School of Medicine
Showing 1-9 of 9 Results
Associate Professor of Pediatrics (Stem Cell Transplantation) at the Lucile Salter Packard Children's Hospital
Current Research and Scholarly Interests Hematopoietic Stem cell biology-created a SCID mouse model to study engraftment of cord blood derived hematopoietic cells and use of this model to develop gene transfer technology for Fanconi anemia.Clinical research interests are to develop new protocols to reduce toxicity from high doses of chemotherapy and radiation therapy and development of a comprehensive late effects clinic for the long term follow up of transplant patients.
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly Interests Bone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia.
Clinical Associate Professor, Pediatrics - Stem Cell Transplantation
Current Research and Scholarly Interests 1. Developing novel bone marrow transplant regimens for patients with hemoglobinopathies
2. Cord blood transplantation
Associate Professor of Pediatrics (Cancer Biology)
Current Research and Scholarly Interests Genome Editing and Population Dynamics for Gene Therapy and Cancer Research
Instructor, Pediatrics - Stem Cell Transplantation
Bio I am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.